Abstract | UNLABELLED: A new generation of intravascular contrast agents, the non-ionic monomers have safety profiles that are superior to those of older ionic compounds. There are, however, significant differences between these agents. AIM: The aim of this study was to determine the incidence of early (<24h) and late (>24h to 7 days) reactions to two non-ionic contrast agents currently used during cardiac catheterisation: iopamidol 340 ( Niopam Bracco UK Ltd.) and iomeprol 350 ( Iomeron Bracco UK Ltd.). METHODS: This was a prospective, randomised, double blinded trial. One thousand nine hundred and eighty-five patients undergoing cardiac catheterisation received one of the following contrast agents on a weekly basis: iopamidol 340 ( Niopam) and iomeprol 350 ( Iomeron). Reactions that were possibly related to the contrast agents were recorded on predefined data collection forms during the first 24h of the procedure (early reaction) and after 24h to 7 days (late reaction) by means of a questionnaire. RESULTS: The baseline characteristics were matched in both the groups. There was no significant difference in the incidence of heat sensation experienced between the two groups (p=0.1). Early non-heat reactions occurred in 2.7% of patients receiving iopamidol 340 ( Niopam) and 4% of those receiving iomeprol 350 ( Iomeron) (p=0.1). Significant electrocardiographic changes were recorded in 1.7% of patients who received iopamidol 340 ( Niopam), and 1% of those who received iomeprol 350 ( Iomeron) (p=0.2). Bradycardia occurred more frequently in the iopamidol 350 group (0.8%) compared to the iomeprol 350 group (0.1%) p=0.02. Late reactions occurred in 16.2% of those receiving iopamidol 340 ( Niopam) and 21.7% of those receiving iomeprol 350 ( Iomeron) (p=0.02). A total of 23 (3.7%) patients in the iopamidol group and 39 (6.2%) patients in the iomeprol group reported nausea, p=0.01. CONCLUSIONS: The incidence of early adverse reactions was similar with the two non-ionic contrast agents. Although bradycardia was slightly more frequent using iopamidol 340, nausea was reported more commonly 24h after the procedure in patients receiving Iomeron 350 ( Iomeron). We conclude that there were only minor clinical differences between these agents; both are safe and well tolerated.
|
Authors | Kunadian Vijayalakshmi, Babu Kunadian, Robert A Wright, James A Hall, Michael J Stewart, Adrian Davies, Andrew Sutton, Mark A de Belder |
Journal | European journal of radiology
(Eur J Radiol)
Vol. 61
Issue 2
Pg. 342-50
(Feb 2007)
ISSN: 0720-048X [Print] Ireland |
PMID | 17101256
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Contrast Media
- iomeprol
- Iopamidol
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Bradycardia
(chemically induced)
- Cardiac Catheterization
(adverse effects)
- Contrast Media
(administration & dosage, adverse effects)
- Double-Blind Method
- Electrocardiography
- Female
- Hot Temperature
- Humans
- Injections, Intravenous
- Iopamidol
(administration & dosage, adverse effects, analogs & derivatives)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Prospective Studies
- Time Factors
|